C4 Therapeutics, Inc.
NASDAQ:CCCC
5.51 (USD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 15.362 | 12.006 | 3.039 | 3.261 | 11.072 | 2.664 | 3.759 | 2.854 | 6.754 | 13.834 | 7.654 | 20.078 | 8.5 | 9.781 | 7.426 | 8.262 | 8.447 | 9.67 | 6.816 | 8.209 | 5.364 | 3.904 | 3.904 |
| Cost of Revenue
| 2.056 | 2.045 | 2.027 | 1.691 | 1.995 | 1.989 | 2.062 | 2.023 | 1.919 | 2.141 | 1.489 | 0.758 | 24.302 | 23.286 | 20.526 | 19.461 | 23.935 | 17.76 | 16.312 | 16.017 | 12.948 | 9.547 | 9.547 |
| Gross Profit
| 13.306 | 9.961 | 1.012 | 1.57 | 9.077 | 0.675 | 1.697 | 0.831 | 4.835 | 11.693 | 6.165 | 19.32 | -15.802 | -13.505 | -13.1 | -11.199 | -15.488 | -8.09 | -9.496 | -7.808 | -7.584 | -5.643 | -5.643 |
| Gross Profit Ratio
| 0.866 | 0.83 | 0.333 | 0.481 | 0.82 | 0.253 | 0.451 | 0.291 | 0.716 | 0.845 | 0.805 | 0.962 | -1.859 | -1.381 | -1.764 | -1.355 | -1.834 | -0.837 | -1.393 | -0.951 | -1.414 | -1.446 | -1.446 |
| Reseach & Development Expenses
| 31.838 | 23.753 | 22.533 | 30.391 | 28.347 | 29.926 | 29.042 | 30.652 | 29.663 | 31.323 | 26.203 | 26.551 | 24.302 | 23.286 | 20.526 | 20.433 | 23.935 | 17.76 | 16.312 | 16.017 | 12.948 | 9.547 | 9.547 |
| General & Administrative Expenses
| 11.768 | 9.695 | 10.288 | 10.297 | 10.533 | 10.306 | 10.945 | 10.495 | 9.579 | 9.895 | 12.82 | 8.782 | 8.452 | 8.611 | 7.409 | 6.732 | 2.861 | 2.769 | 2.842 | 2.691 | 2.417 | 1.834 | 1.834 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | -1.691 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 11.768 | 9.695 | 10.288 | 8.606 | 10.533 | 10.306 | 10.945 | 10.495 | 9.579 | 9.895 | 12.82 | 8.782 | 8.452 | 8.611 | 7.409 | 6.732 | 2.861 | 2.769 | 2.842 | 2.691 | 2.417 | 1.834 | 1.834 |
| Other Expenses
| -31.838 | 0 | 2.437 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.043 | 0 | 0 | 0.002 | -0.001 | 0 | 0 |
| Operating Expenses
| 43.606 | 33.448 | 35.258 | 38.997 | 38.88 | 40.232 | 39.987 | 41.147 | 39.242 | 41.218 | 39.023 | 35.333 | 32.754 | 31.897 | 27.935 | 27.165 | 26.796 | 20.529 | 19.154 | 18.708 | 15.365 | 1.687 | 1.687 |
| Operating Income
| -28.244 | -21.442 | -32.219 | -37.427 | -27.808 | -37.568 | -36.228 | -38.293 | -32.488 | -27.384 | -31.369 | -15.255 | -24.254 | -22.116 | -20.509 | -18.903 | -18.349 | -10.859 | -12.338 | -10.499 | -10.001 | -7.477 | -7.477 |
| Operating Income Ratio
| -1.839 | -1.786 | -10.602 | -11.477 | -2.512 | -14.102 | -9.638 | -13.417 | -4.81 | -1.979 | -4.098 | -0.76 | -2.853 | -2.261 | -2.762 | -2.288 | -2.172 | -1.123 | -1.81 | -1.279 | -1.864 | -1.915 | -1.915 |
| Total Other Income Expenses Net
| 3.578 | 3.726 | 3.858 | 2.95 | 1.774 | 1.646 | 1.448 | 1.108 | 0.53 | -0.028 | -0.251 | -0.539 | -0.429 | -0.464 | -0.462 | -2.579 | -3.098 | -0.102 | 0.259 | 0.002 | -0.001 | 0.611 | 0.611 |
| Income Before Tax
| -24.666 | -17.716 | -28.361 | -34.477 | -26.034 | -35.922 | -34.78 | -37.185 | -31.958 | -27.412 | -31.62 | -15.658 | -24.683 | -22.58 | -20.971 | -21.919 | -22.002 | -10.961 | -12.079 | -10.119 | -9.444 | -6.866 | -6.866 |
| Income Before Tax Ratio
| -1.606 | -1.476 | -9.332 | -10.573 | -2.351 | -13.484 | -9.252 | -13.029 | -4.732 | -1.981 | -4.131 | -0.78 | -2.904 | -2.309 | -2.824 | -2.653 | -2.605 | -1.134 | -1.772 | -1.233 | -1.761 | -1.759 | -1.759 |
| Income Tax Expense
| -2.056 | -2.045 | -2.027 | 0.277 | -1.003 | 1.788 | -0.842 | -1.108 | -0.53 | 0.028 | 0.251 | 0.539 | 0.11 | 0.069 | 0.072 | -0.124 | -0.167 | -0.168 | -0.167 | -0.096 | 0.65 | 0.125 | 0.125 |
| Net Income
| -24.666 | -17.716 | -28.361 | -34.754 | -27.037 | -35.922 | -33.938 | -36.077 | -31.428 | -27.44 | -31.871 | -15.658 | -24.683 | -22.58 | -20.971 | -21.795 | -21.835 | -10.793 | -11.912 | -10.023 | -10.094 | -9.091 | -9.091 |
| Net Income Ratio
| -1.606 | -1.476 | -9.332 | -10.657 | -2.442 | -13.484 | -9.028 | -12.641 | -4.653 | -1.984 | -4.164 | -0.78 | -2.904 | -2.309 | -2.824 | -2.638 | -2.585 | -1.116 | -1.748 | -1.221 | -1.882 | -2.329 | -2.329 |
| EPS
| -0.35 | -0.26 | -0.41 | -0.68 | -0.55 | -0.73 | -0.69 | -0.74 | -0.64 | -0.56 | -0.66 | -0.32 | -0.51 | -0.51 | -0.49 | -0.53 | -0.54 | -0.26 | -0.69 | -0.58 | -0.59 | -6.76 | -6.76 |
| EPS Diluted
| -0.35 | -0.26 | -0.41 | -0.68 | -0.55 | -0.73 | -0.69 | -0.74 | -0.64 | -0.56 | -0.65 | -0.32 | -0.51 | -0.51 | -0.49 | -0.53 | -0.54 | -0.26 | -0.69 | -0.58 | -0.59 | -6.76 | -6.76 |
| EBITDA
| -28.244 | -21.442 | -32.219 | -35.736 | -27.808 | -35.322 | -34.174 | -36.063 | -30.989 | -26.443 | -30.788 | -14.796 | -23.814 | -21.659 | -19.986 | -17.96 | -18.089 | -10.418 | -11.663 | -10.077 | -9.58 | -7.101 | -7.101 |
| EBITDA Ratio
| -1.839 | -1.786 | -10.602 | -10.959 | -2.512 | -13.259 | -9.091 | -12.636 | -4.588 | -1.911 | -4.022 | -0.737 | -2.802 | -2.214 | -2.691 | -2.174 | -2.141 | -1.077 | -1.711 | -1.228 | -1.786 | -1.819 | -1.819 |